TR200201081A2 - Zayıflatılmış rekombinant kuduz virüs mutantları ve bu mutantların canlı aşıları - Google Patents

Zayıflatılmış rekombinant kuduz virüs mutantları ve bu mutantların canlı aşıları

Info

Publication number
TR200201081A2
TR200201081A2 TR2002/01081A TR200201081A TR200201081A2 TR 200201081 A2 TR200201081 A2 TR 200201081A2 TR 2002/01081 A TR2002/01081 A TR 2002/01081A TR 200201081 A TR200201081 A TR 200201081A TR 200201081 A2 TR200201081 A2 TR 200201081A2
Authority
TR
Turkey
Prior art keywords
mutants
rabies virus
live vaccines
attenuated recombinant
recombinant rabies
Prior art date
Application number
TR2002/01081A
Other languages
English (en)
Other versions
TR200201081A3 (tr
Inventor
Mebatsion Teshome
Original Assignee
Akzo Nobel N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel N.V. filed Critical Akzo Nobel N.V.
Publication of TR200201081A2 publication Critical patent/TR200201081A2/tr
Publication of TR200201081A3 publication Critical patent/TR200201081A3/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Bu bulus, P ve G genlerinin söz konusu oldugu, viral genomun iki farkli kisminda bir kombine mutasyonu içeren rekombinant RV mutantlarini anlatmaktadir. P genindeki mutasyonlar tercihan 139-170 artiklarini, daha tercihan 139-149 artiklarini, en tercih edilen sekilde ise 143-149 artiklarini kapsamaktadir. Mutasyon yukaridaki bölümdeki bir ya da daha çok amino asitin bir ikamesi ya da silintisinin yanisira, silinti ve ikamenin kombinasyonlari olabilmektedir.
TR2002/01081A 2001-04-23 2002-04-19 Zayiflatilmis rekombinant kuduz virüs mutantlari ve bu mutantlarin canli asilari TR200201081A3 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01201464 2001-04-23
EP01203773 2001-10-05

Publications (2)

Publication Number Publication Date
TR200201081A2 true TR200201081A2 (tr) 2002-11-21
TR200201081A3 TR200201081A3 (tr) 2002-11-21

Family

ID=26076884

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/01081A TR200201081A3 (tr) 2001-04-23 2002-04-19 Zayiflatilmis rekombinant kuduz virüs mutantlari ve bu mutantlarin canli asilari

Country Status (10)

Country Link
US (1) US6887479B2 (tr)
EP (1) EP1253197B1 (tr)
AR (1) AR033873A1 (tr)
AT (1) ATE316572T1 (tr)
BR (1) BR0201366A (tr)
CA (1) CA2382993A1 (tr)
DE (1) DE60208854T2 (tr)
ES (1) ES2257505T3 (tr)
PT (1) PT1253197E (tr)
TR (1) TR200201081A3 (tr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51371B (sr) * 2004-07-12 2011-02-28 Thomas Jefferson University, Office Of Technology Transfer Smeše rekombinantnog rabijes virusa
CA2943039C (en) 2005-10-14 2018-11-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Rabies virus compositions and methods
WO2007070678A2 (en) * 2005-12-14 2007-06-21 University Of Georgia Research Foundation, Inc. Rabies vaccine
FR2944292B1 (fr) 2009-04-08 2013-08-23 Sanofi Pasteur Procede de purification du virus rabique
RU2013102929A (ru) * 2010-06-24 2014-07-27 Зе Гавермент Оф Зе Юнайтед Стейтс Оф Америка Эз Репрезентед Бай Зе Секретари Оф Зе Департмент Оф Хэлс Энд Хьюман Сервисез, Сентерз Фо Дизиз Контрол Энд Привеншн Пан-лиссавирусные вакцины против бешенства
US10849975B2 (en) 2011-02-03 2020-12-01 Thomas Jefferson University Multivalent vaccines for rabies virus and filoviruses
WO2017176596A1 (en) 2016-04-04 2017-10-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Multivalent vaccines for rabies virus and coronaviruses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1386100A (en) * 1998-11-27 2000-06-19 Akzo Nobel N.V. Stable, attenuated rabies virus mutants and live vaccines thereof

Also Published As

Publication number Publication date
EP1253197B1 (en) 2006-01-25
DE60208854D1 (de) 2006-04-13
PT1253197E (pt) 2006-06-30
ES2257505T3 (es) 2006-08-01
EP1253197A1 (en) 2002-10-30
US6887479B2 (en) 2005-05-03
DE60208854T2 (de) 2006-08-17
AR033873A1 (es) 2004-01-07
TR200201081A3 (tr) 2002-11-21
ATE316572T1 (de) 2006-02-15
CA2382993A1 (en) 2002-10-23
BR0201366A (pt) 2003-06-10
US20020164356A1 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
DE69937999D1 (de) Interferon induzierende genetisch veränderte attenuierte viren
BR0010361A (pt) Seq ências genÈmicas de neisseria e uso destas
NO20056074L (no) Hoy titer rekombinante influensavira til vaksiner og genterapi
MXPA01003557A (es) Secuencias genomicas de neisseria y metodos para su uso.
MA33440B1 (fr) Nouvelles compositions
SI1554301T1 (sl) VAKCINA ZA DENGO, KI VSEBUJE SKUPNO DELECIJO 30 NUKLEOTIDOV V 3ĹľUTR TIPOV 1 IN 2 DENGE
CY1108520T1 (el) Ανασυνδιασμενοι ιοι γριππης για εμβολια και γονιδιακη θεραπεια
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
NO20082149L (no) Hundeinfluensavirus og relaterte sammensetninger og fremgangsmater for bruk
TR200201081A2 (tr) Zayıflatılmış rekombinant kuduz virüs mutantları ve bu mutantların canlı aşıları
ATE399210T1 (de) Knockout-mutante von vaccinia-virus und verwendung davon
ATE469170T1 (de) Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
HUP0303431A2 (hu) PRRS vírus élő legyengített törzsei
ATE334231T1 (de) Neue polynukleotide und polypeptide des ifn alpha-17-gens
CY1106570T1 (el) Σταθερες, εξασθενημενες μεταλλαγμενες μορφες ιου λυσσας και ζωντανια εμβολια αυτων
DE60118935D1 (de) Dna & protein bindende miniatur proteine
ATE543513T1 (de) Anti-coronavirus impfstoff
WO2007015783A3 (en) Attenuated strains of flaviviruses , and uses thereof
WO2003008571A3 (es) Cadenas quiméricas codificantes para proteínas inductoras de efectos contra virus
WO2002018426A3 (en) Rabbit hemorrhagic disease vaccine and antigens
BR0012556A (pt) Genes e vacinas de ehrlichia canis
ATE453708T1 (de) Impfstoff gegen west nile virus
AR031599A1 (es) Vacunas para el virus herpes equino tipo 1: virus que hospeda mutaciones dentro del gen inmediato precoz
ATE310807T1 (de) Trennung eines humanen retrovirus
GB0415437D0 (en) Recombinant virus